Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia

References

• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230–230.
   PubMed Web of Science ®Google Scholar
• Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32–38.
   PubMed Web of Science ®Google Scholar
• Turner JP, Jamsen KM, Shakib S, et al. Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer. 2016;24(4):1831–1840.
   PubMed Web of Science ®Google Scholar
• Haider SI, Ansari Z, Vaughan L, et al. Prevalence and factors associated with polypharmacy in Victorian adults with intellectual disability. Res Dev Disabil. 2014;35(11):3071–3080.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Ma H, Guo R, et al. Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities. Br J Haematol. 2018;180(2):267–270.
   PubMed Web of Science ®Google Scholar
• Jokanovic N, Tan ECK, Dooley MJ, et al. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535.e1–535.e12.
   Web of Science ®Google Scholar
• Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). 2005;24(Suppl Web Exclusives):W5-152–W5-W166.
   Google Scholar
• Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32(2):169–175.
   PubMed Web of Science ®Google Scholar
• Puts MTE, Costa-Lima B, Monette J, et al. Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging. 2009;26(6):519–536.
   PubMed Web of Science ®Google Scholar
• Prithviraj GK, Koroukian S, Margevicius S, et al. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol. 2012;3(3):228–237.
   PubMed Web of Science ®Google Scholar
• Turner JP, Shakib S, Singhal N, et al. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer. 2014;22(7):1727–1734.
   PubMed Web of Science ®Google Scholar
• Hanigan MH, Dela Cruz BL, Thompson DM, et al. Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract. 2008;14(3):123–130.
   PubMedGoogle Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14(5):447–450.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–19.
   PubMed Web of Science ®Google Scholar
• Zhan C, Arispe I, Kelley E, et al. Ambulatory care visits for treating adverse drug effects in the United States, 1995–2001. Jt Comm J Qual Patient Saf. 2005;31(7):372–378.
   PubMedGoogle Scholar
• Badgwell B, Stanley J, Chang GJ, et al. Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery. J Surg Oncol. 2013;108(3):182–186.
   PubMed Web of Science ®Google Scholar
• Sharma M, Loh KP, Nightingale G, et al. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346–353.
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012;60(1):34–41.
   PubMed Web of Science ®Google Scholar
• Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol. 2013;24(Suppl 7):vii36–vii40.
   PubMedGoogle Scholar
• Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249–1257.
   PubMed Web of Science ®Google Scholar
• Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc. 2014;62(8):1505–1512.
   PubMed Web of Science ®Google Scholar
• Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–522.
   PubMed Web of Science ®Google Scholar
• Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453–1459.
   PubMed Web of Science ®Google Scholar
• Werneke U, Earl J, Seydel C, et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer. 2004;90(2):408–413.
   PubMed Web of Science ®Google Scholar
• Elliot K, Tooze JA, Geller R, et al. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184–1190.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–4336.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Gundabolu K, Koll T, et al. Initial therapy for acute myeloid leukemia in older patients: principles of care. Leuk Lymphoma. 2018;59(1):29–41.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Chen B, Lee SJ. Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: a National Cancer Database Study. Bone Marrow Transplant. 2018;53(7):873–879.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Seynaeve C, Wymenga ANM, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch Breast Cancer Trialists’ Group. Breast. 2014;23(1):81–87.
   PubMed Web of Science ®Google Scholar
• Woopen H, Richter R, Ismaeel F, et al. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol. 2016;140(3):554–558.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Chen B, Gyawali B, et al. Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia. Bone Marrow Transplant. 2018;53(10):1288–1294.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Fullington HM, Alvarez CA, et al. Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer. 2018;124(13):2850–2857.
   PubMed Web of Science ®Google Scholar
• Shay LA, Parsons HM, Vernon SW. Survivorship care planning and unmet information and service needs among adolescent and young adult cancer survivors. J Adolesc Young Adult Oncol. 2017;6(2):327–332.
   PubMed Web of Science ®Google Scholar
• Wu X-C, Prasad PK, Landry I, et al. Impact of the AYA HOPE comorbidity index on assessing health care service needs and health status among adolescents and young adults with cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(12):1844–1849.
   PubMed Web of Science ®Google Scholar
• Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800–4809.
   PubMed Web of Science ®Google Scholar